Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

LiDCO secures two new contracts in the US as its new offering gains traction

AIM-quoted LiDCO has signed up two more hospitals in the US to its new higher-margin, longer-term High Usage Programme
LiDCO blood flow monitoring screen
The HUP model was launched last summer and allows customers unlimited use of LiDCO’s monitoring products for an annual fee

LiDCO Group PLC (LON:LID) was on the up on Wednesday, after the blood flow monitoring products maker told analysts at a capital markets day that it has won a couple of new contracts in the US.

The AIM-quoted firm has signed up two additional customers to its new High Usage Programme (HUP) – a higher margin business model which requires customers to pay in advance for the products and covers a longer period of time.

Pipeline of opportunities continues to increase

Shares were up 12% in early afternoon trading to 7p.

One of the new customers is a trauma centre in New York, while the other is 1,000+ bed hospital in the Mid-West.

The initial orders are for eight monitors in total, but LiDCO expects this number to grow “significantly” once the hospitals realise the benefits of the technology and the unlimited use of LiDCO’s products.

“HUP is having a transformational impact on our US sales and even with the initial success that we have had so far, year to date recurring revenues are up 95% in local currency versus prior year,” said chief executive Matt Sassone.

“We continue to be encouraged by the positive response to our HUP offering. The pipeline of opportunities continues to increase and as we accelerate the speed of conversion of other prospects in this large and growing market, we are confident that we can take further market share.”

View full LID profile View Profile

LiDCO Group plc Timeline

Related Articles

July 30 2018
Life science generally is developing at an incredible speed, says Joe Anderson
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use